Mark Platenburg

Dr. Mark Platenburg

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Current Opinion in Pulmonary Medicine
Verified
Journal Article
Closed access
DKDymph Klay
Dymph Klay
MPMark Platenburg
Mark Platenburg
RRRein H.N.A.J. van Rijswijk
Rein H.N.A.J. van Rijswijk
JGJan C. Grutters
Jan C. Grutters
CMColine H.M. van Moorsel
Coline H.M. van Moorsel
Purpose of review: The current review aims to recognize the variability in clinical presentation of adult patients with bi-allelic ABCA3 mutations, create more depth in ABCA3 mutations reported and highlight the influence of environmental factors on disease course. Recent findings: Mutations in ABCA3 are predominantly linked to neonatal and pediatric interstitial lung disease (ILD) with a minority surviving beyond puberty. Here, we present three patients with ABCA3 mutations who present with disease at the age of 19, 61 and 77. Moreover, we identified c.4451G>C (p.R1484P), c.1675G>A (p.G559R) and c.4745C>G (p.T1582S) as three novel ABCA3 mutations. In addition, we identified six additional patients with ABCA3 mutations in literature who reached an age above 18. Furthermore, we discuss the influence of infections, drugs and smoking on disease course. Summary: Although extremely rare, patients with bi-allelic mutations in ABCA3 may present at adulthood. Late onset of disease may be influenced by type of mutation or environmental factors.

16 January 2020 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
MPMark Platenburg
Mark Platenburg
IWIvo A. Wiertz
Ivo A. Wiertz
JVJoanne J. van der Vis
Joanne J. van der Vis
BCBruno Crestani
Bruno Crestani
RBRaphael borie
Raphael borie
CMColine H.M. van Moorsel
Coline H.M. van Moorsel

9 November 2022 in Chest
Verified
Journal Article
Closed access
DKDymph Klay
Dymph Klay
JGJan C. Grutters
Jan C. Grutters
JVJoanne J van der Vis
Joanne J van der Vis
MPMark Platenburg
Mark Platenburg
JKJohannes C. Kelder
Johannes C. Kelder
CMColine H.M. van Moorsel
Coline H.M. van Moorsel

11 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sofia MollSofia Moll
Sofia Moll
MPMark Platenburg
Mark Platenburg
AVAdriane Dore Marie Vorselaars
Adriane Dore Marie Vorselaars
AVAdriane Dore Marie Vorselaars
Adriane Dore Marie Vorselaars
MBMontse Janssen Bonàs
Montse Janssen Bonàs
JGJan C. Grutters
Jan C. Grutters
Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis autoantibodies in ILD are presented. A total of 1194 patients with ILD and 116 healthy subjects were tested for antibodies specific for Ks, Ha, Zoα, and cN1A with a line-blot assay on serum available at the time of diagnosis. Autoantibodies were demonstrated in 63 (5.3%) patients and one (0.9%) healthy control (p = 0.035). Autoantibodies were found more frequently in females (p = 0.042) and patients without a histological and/or radiological usual interstitial pneumonia (UIP; p = 0.010) and a trend towards CTD-ILDs (8.4%) was seen compared with other ILDs (4.9%; p = 0.090). The prevalence of antibodies specific for Ks, Ha, Zoα, and cN1A was, respectively, 1.3%, 2.0%, 1.4%, and 0.9% in ILD. Anti-Ha and Anti-Ks were observed in males with unclassifiable idiopathic interstitial pneumonia (unclassifiable IIP), hypersensitivity pneumonitis (HP), and various CTD-ILDs, whereas anti-cN1A was seen in females with antisynthetase syndrome (ASS), HP, and idiopathic pulmonary fibrosis (IPF). Anti-Zoα was associated with CTD-ILD (OR 2.5; 95%CI 1.11–5.61; p = 0.027). In conclusion, a relatively high prevalence of previously unknown myositis autoantibodies was found in a large cohort of various ILDs. Our results contribute to the awareness that circulating autoantibodies can be found in ILDs with or without established CTD. Whether these antibodies have to be added to the standard set of autoantibodies analysed in conventional myositis blot assays for diagnostic purposes in clinical ILD care requires further study.

21 June 2023 in Lung
Verified
Journal Article
Closed access
PDF file
MPMark Platenburg
Mark Platenburg
CMColine H. M. van Moorsel
Coline H. M. van Moorsel
IWIvo A. Wiertz
Ivo A. Wiertz
JVJoanne J. van der Vis
Joanne J. van der Vis
AVAdriane D. M. Vorselaars
Adriane D. M. Vorselaars
JGJan C. Grutters
Jan C. Grutters

5 February 2022 in Respiratory Medicine
Verified
Journal Article
Closed access
MPMark Platenburg
Mark Platenburg
JVJ.J. van der Vis
J.J. van der Vis
KKK.M. Kazemier
K.M. Kazemier
JGJ.C. Grutters
J.C. Grutters
CMC.H.M. van Moorsel
C.H.M. van Moorsel